A randomized phase 2 study of Docetaxel with or without Bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

Trial Profile

A randomized phase 2 study of Docetaxel with or without Bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to University Hospital Medical Information Network - Japan record.
    • 01 Feb 2016 Results published in the Cancer.
    • 01 Aug 2012 Study recruitment began in February 2011 and is expected to continue for 2 years, according to the study protocol published in BMC Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top